Clinical trial
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia…
NCT00050843 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00050843 |
|---|---|
| Title | A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | thalidomide |
| Enrollment | 220 |
| Start date | Aug 1, 2001 |
| Completion | Feb 1, 2004 |
| First posted | Dec 24, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: